238 results match your criteria: "S. Giovanni di Dio Hospital[Affiliation]"
Clin Immunol
September 2022
Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Via Torregalli 3, 50143 Florence, Italy.
Background: The soluble urokinase Plasminogen Activator Receptor (suPAR) has been identified as a reliable marker of COVID-19 severity, helping in personalizing COVID-19 therapy. This study aims to evaluate the correlation between suPAR levels and COVID-19 severity, in relation to the traditional inflammatory markers.
Methods: Sera from 71 COVID-19 patients were tested for suPAR levels using Chorus suPAR assay (Diesse Diagnostica Senese SpA, Italy).
Pharmacol Res
September 2022
Rheumatology Unit, ASST-Fatebenefratelli L. Sacco University Hospital, University of Milan, Italy.
Rheumatoid arthritis (RA) is a chronic inflammatory disease whose natural history leads to articular and extra-articular damage. Both cardiovascular risk and malignancy risk results higher in RA patients, compared to general population. Janus kinase inhibitors (JAKis) are oral targeted synthetic disease modifying antirheumatic drugs (tsDMARDs) that disrupt cytokine cascade and exert anti-inflammatory effects by interfering with signaling through the JAK-STAT intracellular pathways.
View Article and Find Full Text PDFAntibiotics (Basel)
May 2022
Clinical Pathology and Microbiology Unit, "S. Giovanni di Dio" Hospital, 88900 Crotone, Italy.
Antimicrobial resistance (AMR) is a serious cause of concern for public health [...
View Article and Find Full Text PDFImmunol Res
August 2022
Immunology and Allergology Laboratory Unit, S.Giovanni di Dio Hospital, Azienda USL-Toscana Centro, Via Torregalli, 3, 50143, Florence, Italy.
Only case reports and small clinical series report the effects of booster vaccination with BNT162b2 in patients with rheumatoid arthritis (RA). We studied 200 patients with RA in clinical remission evaluated with the DAS28. All patients were vaccinated for SARS CoV-2 with the BNT162b2 mRNA vaccine.
View Article and Find Full Text PDFBr J Haematol
July 2022
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
Eur J Clin Pharmacol
July 2022
IRCCS Fondazione Don Carlo Gnocchi, via di Scandicci 269, 50143, Florence, Italy.
Purpose: To assess the impact of long-term use of different drugs commonly prescribed in Alzheimer's disease (AD) on its clinical course and to identify clinical and therapeutic factors associated with a delay in AD progression.
Methods: We retrospectively enrolled 50 patients visited at the Neurology Unit, Careggi University Hospital (Florence), followed for at least 24 months. AD diagnosis was made according to clinical diagnostic criteria for probable/possible AD dementia, always supported at least by one biomarker.
Front Med (Lausanne)
April 2022
UOC Gastroenterologia ed Endoscopia Digestiva, Ospedale Frangipane, Avellino, Italy.
Antibiotics (Basel)
March 2022
Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Results have been implemented with additional data, which have been commented in the following paragraphs [...
View Article and Find Full Text PDFClin Chem Lab Med
May 2022
SOC Clinical Assistance Governance, SOS Preventive Medicine Unit, S. Giovanni di Dio Hospital, Florence, Italy.
Objectives: Evaluating anti-SARS-CoV-2 antibody levels is a current priority to drive immunization, as well as to predict when a vaccine booster dose may be required and for which priority groups. The aim of our study was to investigate the kinetics of anti-SARS-CoV-2 Spike S1 protein IgG (anti-S1 IgG) antibodies and neutralizing antibodies (NAbs) in an Italian cohort of healthcare workers (HCWs), following the Pfizer/BNT162b2 mRNA vaccine, over a period of up to six months after the second dose.
Methods: We enrolled 57 HCWs, without clinical history of COVID-19 infection.
Front Med (Lausanne)
February 2022
Rare Diseases Unit, Azienda USL Toscana Centro, European Reference Network-Skin Member, Department of Health Sciences, University of Florence, Florence, Italy.
Front Biosci (Landmark Ed)
February 2022
Department of Experimental Medicine, University of Tor Vergata, 00133 Rome, Italy.
Background: Several commercial surrogate Virus Neutralization Tests (sVNTs) have been developed in the last year. Neutralizing anti-SARS-CoV-2 antibodies through interaction with Spike protein Receptor Binding Domain (S-RBD) can block the virus from entering and infecting host cells. However, there is a lack of information about the functional activity of SARS-CoV-2 antibodies that may be associated with protective responses.
View Article and Find Full Text PDFItal J Pediatr
February 2022
Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.
Biomedicines
January 2022
Clinical Department of Medical, Surgical and Health Sciences, University of Trieste, 34127 Trieste, Italy.
Acetylsalicylic acid (ASA) is one of the most commonly used drugs in the world. It derives from the extract of white willow bark, whose therapeutic potential was known in Egypt since 1534 BC. ASA's pharmacological effects are historically considered secondary to its anti-inflammatory, platelet-inhibiting properties; however, human studies demonstrating a pro-inflammatory effect of ASA exist.
View Article and Find Full Text PDFClin Rev Allergy Immunol
October 2022
Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
The identification of anti-NXP2 antibodies is considered a serological marker of dermatomyositis (DM), with calcinosis, severe myositis and, in some reports, with cancer. Historically, these associations with anti-NXP2 antibodies have been detected by immunoprecipitation (IP), but in the last few years commercial immunoblotting assays have been released. The aim of this collaborative project was to analyse the clinical features associated to anti-NXP2 antibodies, both with commercial line blot (LB) and IP.
View Article and Find Full Text PDFAntibiotics (Basel)
November 2021
Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Metallo-β-lactamases (MBLs) are among the most challenging bacterial enzymes to overcome. Aztreonam (ATM) is the only β-lactam not hydrolyzed by MBLs but is often inactivated by co-produced extended-spectrum β-lactamases (ESBL). We assessed the activity of the combination of ATM with old and new β-lactamases inhibitors (BLIs) against MBL and ESBL co-producing Gram-negative clinical isolates.
View Article and Find Full Text PDFAntibiotics (Basel)
October 2021
Clinical Chemistry Laboratory, University of Milano-Bicocca, Azienda Socio Sanitaria Territoriale di Monza ASST-Monza, San Gerardo Hospital, via Pergolesi 33, 20900 Monza, Italy.
Background: Cefiderocol is a siderophore cephalosporin that exhibits antimicrobial activity against most multi-drug resistant Gram-negative bacteria, including Enterobacterales, , , and .
Methods: A total of 20 multidrug-resistant strains were isolated from 2020 to 2021, molecularly characterized and tested to assess the in vitro antibacterial activity of cefiderocol. Thirteen strains were carbapenem-hydrolysing oxacillinase OXA-23-like producers, while seven were non-OXA-23-like producers.
Int Immunopharmacol
November 2021
Department of Experimental Medicine, University of Tor Vergata, Rome, Italy; Department of Laboratory Medicine, Tor Vergata University Hospital, Rome, Italy; Emerging Technologies Division, International Federation Clinical Chemistry and Laboratory Medicine, Milan, Italy.
Background And Aims: SARS-CoV-2 antibody assays are relevant in managing the COVID-19 pandemic, providing valuable data on the immunization status of the population. However, current serology tests are highly variable, due to their different characteristics and to the lack of reference materials. The aim of the World Health Organization (WHO) first International Standard (IS) for anti-SARS-CoV-2 immunoglobulin is to harmonize humoral immune response assessment after natural infection or vaccination, and recommend reporting the results for binding activity in Binding Antibody Units (BAU).
View Article and Find Full Text PDFJ Exp Pharmacol
September 2021
U.O.C. Oncologia, "S. Giovanni di Dio" Hospital, ASLNA2NORD, Naples, 80027, Italy.
Despite multimodal treatment, the prognosis of brain metastases (BM) remains limited, with a survival of only a few months. In this report, silibinin (or silybin), a natural polyphenolic flavonoid isolated from seed extracts of the herb milk thistle, is discussed as a potential therapeutic option for the treatment of BM. This molecule has an anticancer effect, blocking the migratory and invasive properties of neoplastic cells.
View Article and Find Full Text PDFAntibiotics (Basel)
August 2021
Clinical Pathology and Microbiology Unit, "S. Giovanni di Dio" Hospital, 88900 Crotone, Italy.
Infections caused by metallo-β-lactamase (MBL)-producing and are increasingly reported worldwide and are usually associated with high mortality rates (>30%). Neither standard therapy nor consensus for the management of these infections exist. Aztreonam, an old β-lactam antibiotic, is not hydrolyzed by MBLs.
View Article and Find Full Text PDFImmunol Res
August 2021
Rheumatology Unit, ASST-Fatebenefratelli L. Sacco University Hospital, University of Milan, Milan, Italy.
Anticancer Agents Med Chem
May 2022
Department of Oncology, S.Luca Hospital, Lucca, Italy.
Background: In advanced non-small-cell lung cancer, without activating mutations and with PD-L1≥50%, Pembrolizumab monotherapy is the therapeutic standard in Europe.
Objective: To evaluate retrospectively the safety and efficacy of this drug and to investigate potential prognostic factors in daily clinical practice.
Methods: From September 2017 to September 2019, 205 consecutive patients from 14 Italian Medical Oncology Units were enrolled in the study.
Autoimmun Rev
October 2021
Department of Health Sciences, Section of Dermatology, USL Toscana Centro, Rare Diseases Unit, European Reference Network-Skin Member, University of Florence, Florence, Italy.
Eur Ann Allergy Clin Immunol
March 2022
Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy.
The purpose of the study was to describe the characteristics of patients experiencing hypersensitivity reactions (HRs) to iodinated contrast media (ICM) in a large Italian population and to investigate potential risks factors in order to obtain a risk stratification, helpful in the management of these patients. Data of 407 patients investigated in 9 Italian Allergy Centers for suspected HRs to ICM were analyzed and compared with a control group of 152 subjects that tolerated one or more ICM-enhanced examinations. The univariate and multivariate logistic regression model was used to evaluate associated factors.
View Article and Find Full Text PDFAntibiotics (Basel)
June 2021
Microbiology and Virology Unit, A. Manzoni Hospital, 23900 Lecco, Italy.
Front Immunol
May 2021
Gastroenterology Unit, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences (DIBIC) L. Sacco, Università degli Studi di Milano, Milan, Italy.
Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna), and a viral-vectored vaccine, i.
View Article and Find Full Text PDF